Ivo Meinhold-Heerlein

Last updated

Ivo Meinhold-Heerlein (born 23 March 1969 in Mainz) is a German gynaecologist and obstetrician, honorary professor, university professor and deputy director of the Department of Gynaecology and Obstetrics at the University Hospital RWTH Aachen University. He is known for his work in the fields of molecular characterization of ovarian cancer.

Contents

Biography

Meinhold-Heerlein studied medicine at the Medical University of Lübeck and at the University of Freiburg from 1989 to 1996. In 1996 he finished his doctoral thesis entitled "Implementing the technique of a non-radioactive in situ hybridization of normal tissues using the example of human skin" ("Etablierung der Technik einer nicht-radioaktiven In-situ-Hybridisierung in Normalgewebe am Beispiel der menschlichen Haut"). From 1999 to 2001 he worked as postdoctoral researcher at the Burnham Institute / La Jolla Cancer Research Center, San Diego, USA. He obtained his license in gynaecology and obstetrics in 2006. In 2007 Meinhold-Heerlein was habilitated at the University of Kiel. From 2006 to 2008 he served as the acting head of the Kiel School of Gynaecological Endoscopy. In 2009 Meinhold-Heerlein became deputy director of the Department of Gynaecology and Obstetrics at the University Hospital Aachen. In the same year he obtained his license in "Special Obstetrics and Perinatal Medicine". In 2012 he was appointed as extraordinary professor (e.g. associate professor) on the medical faculty of the RWTH Aachen University. In 2013 he obtained his license in "Gynaecologic Oncology". Meinhold-Heerlein was appointed as honorary associate professor of the University of Cape Town (South Africa) in 2014. He is currently deputy director of the Department of Gynaecology and Obstetrics at the University Hospital RWTH Aachen as well as head of the gynaecological cancer centre and the endometriosis centre of the University Hospital RWTH Aachen. In 2017 he was appointed as university professor (full professor) for gynaecologic oncology at the RWTH Aachen University. [1]

Scientific contribution

At the beginning of his scientific career Meinhold-Heerlein worked with John C. Reed at The Burnham Institute (La Jolla / USA), where he investigated mechanisms to induce aptoptosis and to overcome chemotherapy resistance of ovarian cancer. [2] Those studies evaluated two key signaling pathways – the death receptor as well as the mitochondrial pathway. [2] [3]

Since the cell cycle regulator p53 is known to transactivate both pathways, several studies focused on p53 mutation and expression analyses. Meinhold-Heerlein and coworkers showed that poorly differentiated ovarian cancer harbors p53 mutations to a higher extent than hitherto assumed. [4]

Together with Garret Hampton, Meinhold-Heerlein performed oligonucleotide array analyses and identified novel molecular markers suitable as therapeutic targets. The main focus lay on the evaluation of serous tumors, which represent the majority of ovarian cancer cases. An important finding was that non-invasive tumors of low-malignant potential (so-called borderline tumors) showed a nearly identical expression pattern when compared to highly differentiated invasive carcinomas. Moderate and poorly differentiated carcinomas, by contrast, shared a nearly identical expression pattern with respect to one another but which was significantly different from the former pattern. With these findings Meinhold-Heerlein contributed to the contemporary understanding of serous ovarian cancer in discriminating two significant types: [5] low grade versus high grade.

After returning to Germany, Meinhold-Heerlein continued his research at the University of Kiel with funding from the Deutsche Krebshilfe (German Cancer Aid). Together with Dirk Bauerschlag and Garret Hampton, he identified additional markers suitable as serum markers for early detection of ovarian cancer subgroups. [6] [7] [8]

Currently, in collaboration with Ahmad Hussain and Stefan Barth, he focuses on immunological approaches called theranostics to detect and eliminate ovarian cancer as well as endometriosis. This type of approach involves linking specific antibodies to molecules which help detect and/or eliminate disease-specific cells. [9]

Academic memberships

Honors and awards

Publications

Related Research Articles

<span class="mw-page-title-main">International Federation of Gynaecology and Obstetrics</span> Professional medical organization

The International Federation of Gynaecology and Obstetrics, usually just FIGO ("fee'go") as the acronym of its French name Fédération Internationale de Gynécologie et d'Obstétrique, is a worldwide non-governmental organisation representing obstetricians and gynaecologists in over one hundred territories. It was founded on 26 July 1954 in Geneva, Switzerland, to "promote the well-being of women and to raise the standard of practice in obstetrics and gynaecology". Membership is currently composed of 132 professional societies of obstetricians and gynaecologists worldwide.

<span class="mw-page-title-main">Hermann Johannes Pfannenstiel</span>

Hermann Johannes Pfannenstiel was a German gynecologist born in Berlin.

<span class="mw-page-title-main">Robert Michaelis von Olshausen</span> German obstetrician and gynecologist (1835–1915)

Robert Michaelis von Olshausen was a German obstetrician and gynecologist. He was born in Kiel and died in Berlin. He was the son of Justus Olshausen (1800–82), a professor of Oriental languages at the University of Kiel.

<span class="mw-page-title-main">Franz von Winckel</span> German gynecologist and obstetrician

Franz Karl Ludwig Wilhelm von Winckel was a German gynecologist and obstetrician who was a native of Berleburg.

<span class="mw-page-title-main">Ernst Wertheim</span> Austrian gynecologist (1864–1920)

Ernst Wertheim was an Austrian gynecologist born in Graz.

<span class="mw-page-title-main">Carl Braun (obstetrician)</span> Austrian obstetrician

Carl Braun, sometimes Carl Rudolf Braun alternative spelling: Karl Braun, or Karl von Braun-Fernwald, name after knighthood Carl Ritter von Fernwald Braun was an Austrian obstetrician. He was born 22 March 1822 in Zistersdorf, Austria, son of the medical doctor Carl August Braun.

<span class="mw-page-title-main">Hermann Fehling (physician)</span> German obstetrician and gynecologist

Hermann Johannes Karl Fehling was a German obstetrician and gynecologist who was a native of Stuttgart. He was the son of the chemist Hermann von Fehling (1811-1885).

<span class="mw-page-title-main">Friedrich Schauta</span> Austrian surgeon and gynecologist

Friedrich Schauta was an Austrian surgeon and gynecologist born in Vienna.

<span class="mw-page-title-main">David Berry Hart</span>

Dr David Berry Hart FRSE FRCPE was a Scottish gynaecological surgeon and academic.

<span class="mw-page-title-main">Albert Döderlein</span> German obstetrician and gynecologist

Albert Sigmund Gustav Döderlein was a German obstetrician and gynecologist. He was the father of gynecologist Gustav Döderlein.

<span class="mw-page-title-main">Kurt Semm</span> German gynecologist (1927–2003)

Kurt Karl Stephan Semm was a German gynecologist and pioneer in minimally invasive surgery. He has been called "the father of modern laparoscopy".

<span class="mw-page-title-main">Hans Frangenheim</span> German gynaecologist

Hans Frangenheim was a German gynaecologist and a pioneer in gynecologic laparoscopy.

<span class="mw-page-title-main">Eduard Arnold Martin</span> German obstetrician and gynecologist

Eduard Arnold Martin was a German obstetrician and gynecologist. He was the father of medic Carl Eduard Martin (1838-1907), philologist Ernst Eduard Martin (1841-1910) and obstetrician August Eduard Martin (1847-1933).

<span class="mw-page-title-main">August Eduard Martin</span> German obstetrician and gynecologist

August Eduard Martin was a German obstetrician and gynecologist. His father, Eduard Arnold Martin (1809–1875), was also a specialist in OB/GYN.

<span class="mw-page-title-main">Oxogestone phenpropionate</span> Chemical compound

Oxogestone phenpropionate, also known as xinogestone, as well as 20β-hydroxy-19-norprogesterone 20β-(3-phenylpropionate), is a progestin related to the 19-norprogesterone derivatives which was developed as an injectable hormonal contraceptive, specifically a progestogen-only injectable contraceptive, in the 1960s and early 1970s but was never marketed. It was studied at a dose of 50 to 75 mg once a month by intramuscular injection but was associated with a high failure rate with this regimen and was not further developed. OPP is the 20β-(3-phenylpropionate) ester of oxogestone, which, similarly, was never marketed.

<span class="mw-page-title-main">High-grade serous carcinoma</span> Medical condition

High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic cavity and is mainly found in the ovary. HGSCs make up the majority of ovarian cancer cases and have the lowest survival rates. HGSC is distinct from low-grade serous carcinoma (LGSC) which arises from ovarian tissue, is less aggressive and is present in stage I ovarian cancer where tumours are localised to the ovary.

<span class="mw-page-title-main">Jalid Sehouli</span> German gynaecologist and oncologist (born 1968)

Jalid Sehouli is a German gynaecologist and oncologist who specializes in peritoneal and ovarian cancer. He is a professor at Berlin's Charité hospital and a writer of scientific as well as fiction works.

<span class="mw-page-title-main">Estradiol benzoate/progesterone</span> Drug combination

Estradiol benzoate/progesterone (EB/P4), sold under the brand names Duogynon and Sistocyclin among others, is a combination medication of estradiol benzoate (EB), an estrogen, and progesterone (P4), a progestogen. It has been formulated both as short-acting oil solutions and long-acting microcrystalline aqueous suspensions and is given by injection into muscle either once or continuously at regular intervals.

Emil Knauer was an Austrian gynecologist and obstetrician.

<span class="mw-page-title-main">Rolf Kreienberg</span> German gynaecologist and obstetrician (1946–2021)

Rolf Kreienberg was a German gynaecologist and obstetrician.

References

  1. 1 2 3 Meinhold-Heerlein CV [ permanent dead link ]
  2. 1 2 I. Meinhold-Heerlein, F. Stenner-Liewen, H. Liewen, S. Kitada, M. Krajewska, S. Krajewski, J. M. Zapata, A. Monks, D. A. Scudiero, T. Bauknecht, J. C. Reed: Expression and potential role of Fas-Associated Phosphatase-1 in Ovarian Cancer. In: Am J Pathol. 158, Nr. 4, 2001, S. 1335–1344.
  3. ↑ M. Krajewska, J. M. Zapata, I. Meinhold-Heerlein, H. Hedayat, A. Monks, A. Shabaik, L. Bubendorf, O. P. Kallioniemi, H. Kim, G. Reifenberger, S. Krajewski, J. C. Reed: Expression of Bcl-2 family member Bid in normal and malignant tissues. In: Neoplasia. 4, Nr. 2, 2002, S. 129–140.
  4. ↑ I. Meinhold-Heerlein, E. Ninci, H. Ikenberg, T. Brandstetter, I. Schwenk, A. Straub, B. Schmitt, H. Bettendorf, C. Ihling, R. Iggo, T. Bauknecht: Evaluation of methods to detect p53 mutations in ovarian cancer. In: Oncology. 60, Nr. 2, 2001, S. 176–188.
  5. ↑ I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitriov, L. Sapinoso, M. Orlowska-Volk, T. Bauknecht, T-W. Park, W. Jonat, A. Jacobsen, J. Sehouli, M. Krajewska, S. Krajewski, J. C. Reed, N. Arnold, G. M. Hampton: Molecular and prognostic distinction between serous ovarian tumors of low and high malignant potential. In: Oncogene. 24, Nr. 6, 2005, S. 1053–1065.
  6. ↑ I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson jr., K. Bräutigam, J. Sehouli, E. Stickeler, D. Könsgen, F. Hilpert, C. von Kaisenberg, J. Pfisterer, T. Bauknecht, Jonat W, Arnold N, Hampton GM: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. In: Clin Cancer Res. 13, Nr. 2, 2007, S. 658–666.
  7. ↑ D. O. Bauerschlag, N. Maass, P. Leonhardt, F. A. Verburg, U. Pecks, F. Zeppernick, A. Morgenroth, F. Mottaghy, R. Tolba, I. Meinhold-Heerlein*, K. Bräutigam*: Fatty Acid Synthase Overexpression: Target for Therapy and Reversal of Chemoresistance in Ovarian Cancer. In: J Transl Med. 13, 2015, S. 146 *co-directed this study.
  8. ↑ K. Bräutigam, J. Biernath-Wüpping, D. O. Bauerschlag, C. S. von Kaisenberg, N. Arnold, W. Jonat, N. Maass, I. Meinhold-Heerlein: Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. In: J Cancer Res Clin Oncol. 137, Nr. 5, 2010, S. 875–886.
  9. ↑ D. O. Bauerschlag*, I. Meinhold-Heerlein*, A. Bleilevens, K. Bräutigam, W. Al Rawashdeh, S. Di Fiore, A. M. Haugg, F. Gremse, J. Steitz, N. Maass, R. Fischer, E. Stickeler, S. Barth, A. F. Hussain: Detection and specific elimination of EGFR+ ovarian cancer cells using a near infrared photoimmunotheranostic approach. In: Pharm Res J 34, Nr. 4, 2017, S. 696–703 *contributed equally to this study.
  10. 1 2 <AGO-online>
  11. ↑ Endometriose SEF.de
  12. ↑ Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: Preisverleihungen auf dem DGGG-Kongress 2010
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.